The Latest Breaking News from Medicare

At Whitman-Walker Health, Dr. David Fessler and his staff administer high-dose influenza vaccine to all HIV-positive and senior patients. Although the vaccine is roughly three times as expensive as standard flu vaccine, it seems to do a better job at protecting those with weakened immune systems — a major focus…

Often poor oral health can lead to social isolation, mental health issues and other serious illnesses. Advocates are calling on both sides of politics to commit to improving dental programs for older people.

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Medicare has decided once and for all not to pay for Biogen’s new Alzheimer’s drug Aduhelm unless patients are enrolled in a clinical study.

After fleeing Ukraine with just some clothes and a computer, the 43-year-old worries about her future in Australia with no end to the invasion in sight

Medical training embedded in regional Australia is often hailed as the best way to keep doctors in the country, but experts say there is more to it.

Medicare officially restricted use of Biogen's Alzheimer's treatment, Aduhelm, to patients enrolled in clinical studies.

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

The Biden administration announced Medicare will cover Aduhelm, but will require patients to be enrolled in a clinical trial in order to access the drug.

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.